報價延遲最少15分鐘:2025/11/18 09:14 EST
盤前時段
|
||||
|
18.3 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
--
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.96/--
|
|
企業價值
1.67B
|
| 資產負債 |
|
每股賬面淨值
2.88
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
9.04M
|
|
每股收益
0.07
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/11/18 09:14 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others. |
